Saginaw Psychological Services, Inc. | |
2100 Hemmeter Rd Saginaw MI 48603-3944 | |
(989) 799-2100 | |
(989) 799-2637 |
Full Name | Saginaw Psychological Services, Inc. |
---|---|
Speciality | Psychologist |
Location | 2100 Hemmeter Rd, Saginaw, Michigan |
Authorized Official Name and Position | Nathalie Menendes (COO) |
Authorized Official Contact | 9897992100 |
Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
Mailing Address | Practice Location Address |
---|---|
Saginaw Psychological Services, Inc. 2100 Hemmeter Rd Saginaw MI 48603-3944 Ph: (989) 799-2100 | Saginaw Psychological Services, Inc. 2100 Hemmeter Rd Saginaw MI 48603-3944 Ph: (989) 799-2100 |
NPI Number | 1821163882 |
---|---|
Provider Enumeration Date | 11/22/2006 |
Last Update Date | 07/21/2021 |
Certification Date | 07/21/2021 |
Medicare PECOS PAC ID | 8426961467 |
---|---|
Medicare Enrollment ID | O20040216000823 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Identifier | Type | State | Issuer |
---|---|---|---|
1821163882 | NPI | - | NPPES |
680F31140 | Other | MI | BCBS |
730195 | Medicaid | MI | |
800G36205 | Other | MI | BCBS |
700G36088 | Other | MI | BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (Michigan) | Secondary |
103T00000X | Psychologist | (Michigan) | Primary |
104100000X | Social Worker | (Michigan) | Secondary |
Provider Name | Janice C Jones |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1659459881 PECOS PAC ID: 0143278739 Enrollment ID: I20050111000148 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Barbara M Goss |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1063549673 PECOS PAC ID: 2062500911 Enrollment ID: I20071112000141 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Daniel J Petersen |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1740458538 PECOS PAC ID: 1759412984 Enrollment ID: I20100701000389 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jan J Gaertner |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1750669933 PECOS PAC ID: 2062685373 Enrollment ID: I20111102000461 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Kristen Kolberg |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1730359373 PECOS PAC ID: 1456526557 Enrollment ID: I20111219000129 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Tonya Devol Sims |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1669546735 PECOS PAC ID: 0840439196 Enrollment ID: I20130617000435 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Ashley R Luplow |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1942526744 PECOS PAC ID: 4183853203 Enrollment ID: I20140212000389 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Danny Berry |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1588038004 PECOS PAC ID: 0143507889 Enrollment ID: I20170504002391 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Deanna Dubay |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1346898228 PECOS PAC ID: 6507196771 Enrollment ID: I20191001003334 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Kia Jones-mastin |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1982881017 PECOS PAC ID: 6406284629 Enrollment ID: I20200320001877 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Renee M Echartea-steckert |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1982224101 PECOS PAC ID: 2769812338 Enrollment ID: I20200422001602 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Janissee L Daniel |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1588299309 PECOS PAC ID: 1557792751 Enrollment ID: I20200501002491 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jessica J Nobbs |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1720405749 PECOS PAC ID: 9638591506 Enrollment ID: I20200623000434 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Cynthia Lynn Mai |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1720606098 PECOS PAC ID: 7416371349 Enrollment ID: I20200723003042 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Anne Wininger |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1356529580 PECOS PAC ID: 4880018605 Enrollment ID: I20200727000133 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jacob A Garlick |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1982194569 PECOS PAC ID: 7214352509 Enrollment ID: I20200804000822 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Taylor Thelen |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1497314595 PECOS PAC ID: 0749697431 Enrollment ID: I20210324002602 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Sarfaraz Jasdanwala |
---|---|
Provider Type | Practitioner - Internal Medicine |
Provider Identifiers | NPI Number: 1851646665 PECOS PAC ID: 8426364258 Enrollment ID: I20210326002179 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jennifer Ordway |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588253819 PECOS PAC ID: 6406265529 Enrollment ID: I20210430002432 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jasmine E Martinez |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1780241869 PECOS PAC ID: 0840609392 Enrollment ID: I20210513000106 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Melissa Ann Duron |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1588238455 PECOS PAC ID: 5890194039 Enrollment ID: I20210520001901 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Claire Zwerk |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1376101899 PECOS PAC ID: 6103226030 Enrollment ID: I20210615002344 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Bailey M Ross |
---|---|
Provider Type | Practitioner - Psychologist Billing Independently |
Provider Identifiers | NPI Number: 1740640440 PECOS PAC ID: 0143629667 Enrollment ID: I20210712001979 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Courtney Clark |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1265978712 PECOS PAC ID: 3779987946 Enrollment ID: I20210810002703 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Brooke Maylee |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1275928210 PECOS PAC ID: 8224434733 Enrollment ID: I20210909000258 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Whitney Wenglikowski |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1487202016 PECOS PAC ID: 8123419215 Enrollment ID: I20211228001188 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Theresa Steele |
---|---|
Provider Type | Practitioner - Psychologist Billing Independently |
Provider Identifiers | NPI Number: 1326518499 PECOS PAC ID: 4284028739 Enrollment ID: I20220225001036 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Nicole Bailey |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1184060436 PECOS PAC ID: 5294129730 Enrollment ID: I20220228001812 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jennifer Skinner |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1275104150 PECOS PAC ID: 2264828581 Enrollment ID: I20220413000323 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Nicole Creek |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1194172080 PECOS PAC ID: 2567840861 Enrollment ID: I20220527000150 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Tania Leachman |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1558738005 PECOS PAC ID: 8426437518 Enrollment ID: I20220621000667 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Stacey Mumby |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1891319976 PECOS PAC ID: 6103207253 Enrollment ID: I20220720002204 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jenna Morin |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1629529847 PECOS PAC ID: 4082085287 Enrollment ID: I20230126001803 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Stacy Renae Brown |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1255046249 PECOS PAC ID: 1557733987 Enrollment ID: I20230214000766 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Destiny Reikowsky |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1518450840 PECOS PAC ID: 6103285036 Enrollment ID: I20230710002610 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Claire Mariano |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1275107815 PECOS PAC ID: 1557722436 Enrollment ID: I20230726000628 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Chelsee Baker |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1316512510 PECOS PAC ID: 6608239702 Enrollment ID: I20230822003132 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Moregan Lamarr |
---|---|
Provider Type | Practitioner - Clinical Social Worker |
Provider Identifiers | NPI Number: 1801325246 PECOS PAC ID: 4183087745 Enrollment ID: I20230829004263 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Melissa Wazny |
---|---|
Provider Type | Practitioner - Nurse Practitioner |
Provider Identifiers | NPI Number: 1114707445 PECOS PAC ID: 4486009958 Enrollment ID: I20231018003392 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Andrew Keeley |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1821530965 PECOS PAC ID: 6709238306 Enrollment ID: I20240119000405 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Michele Hugo |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1457487886 PECOS PAC ID: 9436501871 Enrollment ID: I20240122001020 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Renate Galloway |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1407214513 PECOS PAC ID: 7012369457 Enrollment ID: I20240122001203 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Darlene White |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1194364885 PECOS PAC ID: 2769834118 Enrollment ID: I20240122001558 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Steven Berman |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1962926899 PECOS PAC ID: 8426400888 Enrollment ID: I20240122001867 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Amy Hayes |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1164500468 PECOS PAC ID: 6204288673 Enrollment ID: I20240122002083 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Jaclynn Nolan |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1396375200 PECOS PAC ID: 7012369325 Enrollment ID: I20240122003968 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Kristy Gustavson |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1730692336 PECOS PAC ID: 0648603944 Enrollment ID: I20240124002852 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Provider Name | Victor Jurkowski |
---|---|
Provider Type | Practitioner - Mental Health Counselor |
Provider Identifiers | NPI Number: 1417199936 PECOS PAC ID: 5597118323 Enrollment ID: I20240129002562 |
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
News Archive
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.
Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, today announced the release of new findings concerning the effect of Bacillus-derived Hyaluronic Acid (HA) on the drug release of tramadol hydrochloride. The new research is to be presented as a scientific poster at the 2013 Controlled Release Society (CRS) annual meeting, July 21-24, Hawaii, USA.
SurgiCount Medical, the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (the "Company", OTCBB: PSTX, OTCQB: PSTX) today announced it has been awarded an Innovative Technology agreement by Novation, the leading healthcare supply chain expertise, analytics and contracting company for the more than 65,000 members of VHA, UHC, Children's Hospital Association and Provista, LLC.
Pharmacyclics, Inc. today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to chemoimmunotherapy.
› Verified 8 days ago
Manc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4705 Towne Ctr, Ste. 201, Saginaw, MI 48604 Phone: 989-799-2770 Fax: 989-799-2737 | |
Cope Personal Developmental Center Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 100 S Jefferson Ave Ste 104, Saginaw, MI 48607 Phone: 989-752-6319 Fax: 989-752-0895 | |
Mind Body- Eft Thearpy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2438 Gatesboro Dr W, Saginaw, MI 48603 Phone: 989-274-4006 | |
Dahlia Therapy Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3854 Dale Rd, Saginaw, MI 48603 Phone: 989-891-7854 | |
Saginaw Psychological Services Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2100 Hemmeter Rd, Saginaw, MI 48603 Phone: 989-799-2100 Fax: 989-799-2637 | |
Saginaw Psychological Services Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2100 Hemmeter Rd, Saginaw, MI 48603 Phone: 989-799-2100 Fax: 989-799-2637 | |
Mind Body-eft Therapy Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2438 Gatesboro Dr W, Saginaw, MI 48603 Phone: 989-274-4006 |